Highest-materiality recent filing
Aspira Women's Health enters $1.05M subordinated loan with Agile Lending, matures Jan 2027
Principal $1,050,000; interest charges $441,000; maturity January 26, 2027.
Aspira Women's Health CEO Michael Buhle departs; Chairman John Fraser named interim CEO
Michael Buhle ceased as CEO effective June 17, 2026; no disagreement with company operations.
Aspira Women's Health raises ~$1.5M in private placement of common stock and warrants
Issued 3.3M shares and warrants to purchase up to 4.455M shares at $0.45 per unit.
Aspira Women's Health appoints John Strahley as CFO; Brian Hungerford departs
Brian Hungerford's consulting agreement terminated at his request effective April 26, 2026, for personal reasons.
Aspira Women's Health enters $10M equity line with Lincoln Park Capital
Lincoln Park committed to purchase up to $10M of Aspira common stock at company's discretion over 24 months.
Aspira Women's Health signs 5-year lab services pact with Mayo Clinic
Aspira will provide Ova1Plus and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical purposes.
Aspira Women's Health Q3 revenue flat at $2.3M; gross margin expands to 64.1%
Nine-month gross profit $4.5M (+12.2% YoY); margin 64.1% vs 58.4%.
Amendment requires Aspira to file Form S-1 by Sept 30, 2025 to register shares and warrant shares.
Aspira Women's Health raises $3.06M in private placement at $0.45/unit, issues 6.55M shares
Gross proceeds $2.95M from sale of 6.55M shares and 4.91M warrants at $0.45/unit; plus $112.5K from exercise of 450K warrants.
Aspira Women's Health appoints Brian Hungerford as CFO, $300K salary, 100K options
Brian Hungerford appointed CFO and Principal Accounting Officer, effective September 2, 2025, replacing Julie Carrillo.
Aspira Women's Health says ARPA-H terminated $10M ENDOinform contract after receiving $3.5M
ARPA-H terminated $10M contract for ENDOinform test on June 9, 2025, citing unmet Milestone 3 specs.
Aspira Q1 revenue up 5.9% to $2.28M; gross margin 68.5%, cash burn reduced 30%
Revenue $2.28M vs $2.15M YoY (+5.9%), driven by select price increases and 94% jump in sales per FTE.
Aspira Women's Health receives Nasdaq delisting notice for failure to meet equity minimum
Received written notice on April 15, 2025 that Nasdaq Hearings Panel determined to delist shares due to non-compliance with Listing Rule 5550(b)(1).
Aspira Women's Health raises up to $2M via discounted equity; appoints three new directors
Equity purchase agreement with Triton Funds for up to $2M; first tranche 354,988 shares for $25,000.
Aspira Women's Health Q4 product revenue up 9.5% to $2.3M; FY revenue flat at $9.2M
Q4 product revenue $2.3M (+9.5% YoY); OvaSuite tests ~6,004 (+6.1%); AUP $391 (+4.3%); gross margin 63.4% (+6.2 ppts).
Aspira Women’s Health VP of Finance James Crawford resigns effective April 4, 2025
James Crawford informed CEO Mike Buhle of his resignation as VP of Finance on March 21, 2025.
Received Nasdaq notice Feb 11, 2025 for violating Rule 5635(c) by issuing shares/warrants below market value without shareholder approval.
Aspira Women's Health receives Nasdaq delisting notice for MVLS non-compliance
Notice received Dec 31, 2024; company failed to regain $35M MVLS requirement by Dec 30, 2024 deadline.
Aspira Women's Health CEO Sandford steps down; Dr. Milligan interim CEO
CEO Nicole Sandford departs immediately for family health matter; remains as consultant for transition.
Aspira Women's Health awarded $10M ARPA-H grant for endometriosis blood test
Selected by ARPA-H for Sprint for Women's Health; $10M funding over two years to develop ENDOinform blood test for endometriosis.
Aspira Women's Health gets $10M ARPA-H award for endometriosis blood test
Selected by ARPA-H for $10 million in milestone-based funding over two years to develop EndoMDx blood test for endometriosis.
Aspira Women's Health receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on Oct 17, 2024 for non-compliance with minimum bid price ($1.00) for 30 consecutive business days.
Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M
Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).
ATM agreement with H.C. Wainwright to sell up to $4,450,000 of common stock from time to time.
Holder exercises warrants for 1,711,111 shares at reduced $1.25 (down from $4.13) for $2.14M gross proceeds.
Aspira Women's Health receives Nasdaq deficiency notice for market value below $35M
Nasdaq notified AWH that MVLS was below $35M minimum for 30 consecutive business days.
Aspira Women's Health announces $1.935M private placement of 1.26M shares and warrants
Gross proceeds ~$1.935M from sale of 1,264,739 shares and accompanying warrants at $1.53 per unit.
Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026
appointed John (Jack) Fraser as Interim Chief Executive Officer
Effective June 17, 2026, the board of directors (the “Board”) of the Company appointed John Fraser, the Company’s current Chairman of the Board, to serve as its Interim Chief Executive Officer while a search of internal and external candidates is conducted.
On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company").
On April 26, 2026, the consulting agreement between the Company and Hungerford Consulting LLC, under which Brian Hungerford had served as Chief Financial Officer, terminated at the request of Hungerford Consulting LLC.
On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.
On April 6, 2025, the Board appointed John Fraser and Cynthia Hundorfean as directors of the Company.
On April 6, 2025, the Board appointed John Fraser and Cynthia Hundorfean as directors of the Company.
On April 2, 2025, the Board (the “Board”) of Directors of the Company appointed Jeffrey Cohen, M.D. as a director of the Company.
On April 4, 2025, the Board appointed Julie Carrillo, the Company’s Corporate Controller, to act as the Principal Accounting Officer of the Company on an interim basis.
On March 21, 2025, James Crawford informed Mike Buhle, the Chief Executive Officer of Aspira Women’s Health Inc. (the “Company”) that he was resigning as VP of Finance of the Company, for personal reasons, effective April 4, 2025.
On March 15, 2025, Celeste Fralick informed the Board of Directors of Aspira Women’s Health Inc. (the “Company”) that she was resigning as a director of the Company, for personal reasons, effective March 31, 2025.
Max materiality 0.90 · Median 0.60 · Most common event other_material